SalaryGuide
AboutPricingFor Employers

Marketing jobs

1 marketing jobs

argenx logo
4 weeks ago

Sr. Director, Patient Marketing Dual Asset Strategy

argenx

Boston, MA (On-site)Full time$236K/yr – $325K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

1 jobs
argenx logo

Sr. Director, Patient Marketing Dual Asset Strategy

argenx

Boston, MA (On-site)

$236K/yr - $325K/yrIn-houseFull-timeSenior level12+ years exp.
4 weeks ago
argenx logo
argenx

Sr. Director, Patient Marketing Dual Asset Strategy

Boston, MA (On-site)

$236K/yr – $325K/yrSenior Level12+ years expFull time

Posted 4 weeks ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own the patient commercial strategy for CIDP and MMN with franchise-level shaping, cross-functional alignment, and a focus on lifecycle progression and competitive distinction.

  • Franchise strategy and market shaping: set the vision, sequencing, and differentiation to lift top of funnel and lifecycle value.
  • Omnichannel and performance: drive disciplined measurement and agile optimization across channels to grow awareness, initiation, and persistence.
  • Cross-functional partnerships: align HCP, Market Access, Medical, Patient Support, and Advocacy to reduce friction and accelerate patient journeys.

Job Description

Responsibilities

  • Lead the development and evolution of patient commercial strategy to maximize growth across CIDP and MMN.
  • Identify and unlock growth levers across awareness, consideration, therapy initiation, persistence, and lifecycle management.
  • Strengthen competitive positioning and reinforce differentiated value within the treatment paradigm.
  • Drive omnichannel optimization using rigorous performance analytics and agile measurement.
  • Expand addressable market through targeted patient segment strategies and ecosystem partnerships.
  • Partner closely with HCP, Market Access, Medical, Patient Support Services and Patient Advocacy to remove friction points across the patient journey.
  • Co-Lead proactive competitive response planning and scenario modeling.
  • Define clear roles, positioning, and treatment sequencing for Vyvgart and Empa across CIDP and MMN.
  • Develop a franchise-level value narrative that clarifies differentiation while reinforcing complementary strengths.
  • Prevent internal cannibalization through disciplined segmentation and treatment pathway strategy.

Requirements

  • 12-15+ years of biopharma commercial experience.
  • Demonstrated success driving performance of an in-market brand.
  • Launch experience required.
  • Experience managing multi-asset or multi-indication portfolios strongly preferred.
  • MBA or advanced degree preferred.

Preferred

  • Deep patient marketing expertise in specialty or rare disease markets preferred.

Benefits

  • This job is eligible to participate in our short-term and long-term incentive programs, subject to the terms and conditions of those plans and applicable policies.
  • It also includes a comprehensive benefits package, including but not limited to retirement savings plans, health benefits and other benefits subject to the terms of the applicable plans and program guidelines.
argenx logo

argenx

3.3 Glassdoor

argenx is a global immunology company committed to improving the lives of people living with severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx is translating immunology breakthroughs into a world-class portfolio of novel antibody-based medicines.

Founded in 2008
Boston, Massachusetts, USA
2K employees (115 in marketing)
www.argenx.com
44% recommend to a friend

Traffic Signals

Monthly Visitors
53.8K
Traffic Source Mix
Search
53.7%
Direct
36.8%
Referral
6.5%
Social
1.5%
Paid
1.3%

Headcount Trend

Current headcount: ~2K

Marketing Team

Marketing Team Size
107 (5% of company)
Marketing Roles Posted (Last 30 Days)
1

Funding

Total Funding
$2B
Last Raise
Post IPO Equity, 5 years ago

Recent News

Are argenx Shares Still at a Discount After Clinical Trial Wins and 48% Rally?
Nov 19, 2025 • Yahoo Finance
argenx Announces Results of Extraordinary General Meeting of Shareholders
Nov 18, 2025 • GlobeNewswire
Here’s Why argenx SE (ARGX) Rose in Q3
Nov 13, 2025 • Yahoo Finance
Evaluating argenx (ENXTBR:ARGX): Does Market Momentum Reflect True Valuation?
Nov 7, 2025 • Yahoo Finance
Argenx NV ADR stock hits all-time high of 855.68 USD
Nov 6, 2025 • Investing.com
Piper Sandler raises argenx stock price target to $930 on strong Vyvgart sales
Nov 4, 2025 • Investing.com
argenx SE (ARGX) Rose due to Increased Sales of its Vyvgart Medication
Nov 3, 2025 • Yahoo Finance
argenx SE stock price target raised to $1,146 from $800 at TD Cowen
Oct 31, 2025 • Investing.com
argenx (ENXTBR:ARGX) Earnings Beat Growth Expectations, Reinforcing Bull Case on Margins and Valuation
Oct 31, 2025 • Yahoo Finance
argenx SE (ARGNF) Q3 2025 Earnings Call Highlights: Record Sales and Strategic Pipeline Advancements
Oct 30, 2025 • Yahoo Finance
argenx Reports Third Quarter 2025 Financial Results and Provides Business Update
Oct 30, 2025 • GlobeNewswire
Argenx pulls back curtain on Vyvgart trial win as part of mission to ensure 'no MG patient is left behind'
Oct 29, 2025 • Fierce Pharma
argenx Presents New Data at AANEM and MGFA Highlighting the Strength and Broad Benefit of VYVGART for Myasthenia Gravis Patients
Oct 29, 2025 • Investing News Network
argenx (ARGX): ADAPT SERON shows 3.35-point MG-ADL improvement in seronegative gMG
Oct 29, 2025 • Stock Titan
argenx Presents New Data at AANEM and MGFA Highlighting the
Oct 29, 2025 • GlobeNewswire
Citi Remains Bullish on Argenx SE (ARGX)
Oct 28, 2025 • Yahoo Finance
argenx to Report Third Quarter 2025 Financial Results and Business Update on October 30, 2025
Oct 22, 2025 • Yahoo Finance
Should You Be Confident in Argenx SE’ (ARGX) Long-Term Profit Cycle?
Oct 15, 2025 • Yahoo Finance
Analyzing argenx (ENXTBR:ARGX) Valuation Following Recent Share Price Strength
Oct 12, 2025 • Yahoo Finance
Argenx NV stock hits all-time high at 803.95 USD
Oct 8, 2025 • Investing.com
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
Oct 3, 2025 • Yahoo Finance
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
Oct 3, 2025 • GlobeNewswire
argenx announces Extraordinary General Meeting of Shareholders on November 18, 2025
Oct 3, 2025 • Stock Titan
Argenx stock hits all-time high at 781.12 USD
Oct 1, 2025 • Investing.com
Oppenheimer Reaffirms Its Outperform Rating on argenx SE (ARGX)
Oct 1, 2025 • Yahoo Finance
Fierce Pharma Asia—Celltrion's Lilly plant buy; Rexulti's PTSD snub; Glenmark, Hengrui's ADC deal
Sep 26, 2025 • FiercePharma
Fujifilm Biotechnologies cuts ribbon on $3.2B antibody facility in N.C.
Sep 24, 2025 • FiercePharma
Are Medical Stocks Lagging Argenx (ARGX) This Year?
Sep 23, 2025 • Yahoo Finance
Vor Biopharma Appoints Navid Z. Khan as Chief Medical Affairs Officer
Sep 23, 2025 • MarketScreener
Biotech specialist Argenx joins Euro Stoxx 50 index
Sep 22, 2025 • belganewsagency.eu
FUJIFILM Biotechnologies and argenx expand global partnership
Sep 19, 2025 • Pharmaceutical Technology
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
Sep 19, 2025 • BioSpace
FUJIFILM Biotechnologies Expands Strategic Partnership with argenx to Include U.S. Manufacturing Operations
Sep 18, 2025 • Yahoo Finance
Fujifilm, argenx expand partnership to bring Vyvgart production to the US
Sep 18, 2025 • FiercePharma
Argenx price target raised by $85 at Stifel, here's why
Sep 18, 2025 • thefly.com
Roivant, Pfizer’s Therapy Shows ‘Patient-Centered Benefit’ in Rare Inflammatory Condition
Sep 18, 2025 • BioSpace
From Sand to Spotlight: Volleyball Star Bourne Turns Battle with Rare Disease into National Honor for Myositis Awareness
Sep 17, 2025 • EIN Presswire
Argenx assumed with a Buy at Truist
Sep 15, 2025 • thefly.com
U.S. Futures Drop, European Stocks Rise
Sep 12, 2025 • Morningstar.com
argenx SE (ARGX) Expands Autoimmune Leadership with Vyvgart Launch
Sep 11, 2025 • Yahoo Finance
A Closer Look at argenx (ENXTBR:ARGX) Valuation Following Positive VYVGART Study Results and Label Expansion Plans
Sep 8, 2025 • Yahoo Finance
BofA Securities reaffirms Buy rating on argenx stock with $887 target
Sep 8, 2025 • Investing.com
Why Dianthus Therapeutics, Up 47% In Four Weeks, Just Surged Again
Sep 8, 2025 • Investor's Business Daily
Argenx stock hits all-time high at 716.89 USD
Sep 3, 2025 • Investing.com
Raya Therapeutic Announces Selection of one of its 5 compounds onto the EXPERTS-ALS Clinical Platform Trial
Sep 2, 2025 • EIN Presswire
Deutsche Bank, Siemens Energy, Argenx to Replace Nokia, Stellantis, Pernod Ricard in Euro Stoxx 50
Sep 2, 2025 • MarketScreener
Euro Stoxx 50 Adds Deutsche Bank, Siemens Energy, Argenx
Sep 2, 2025 • MarketScreener
Hemab Therapeutics Appoints Anant Murthy, PhD, as Chief Operating Officer
Sep 2, 2025 • citybiz
3 Healthcare Pathbreakers With Long-Term Tailwinds
Sep 1, 2025 • MarketBeat
Euro Stoxx 50 Adds Deutsche Bank, Siemens Energy, Argenx
Sep 1, 2025 • Morningstar.com
Sanofi breaks new ground for BTK drugs with ITP approval
Sep 1, 2025 • pharmaphorum
Deutsche Bank and Siemens Energy Join Euro Stoxx 50 Index
Sep 1, 2025 • MarketScreener
The week in pharma: action, reaction and insight – week to August 29
Aug 31, 2025 • Pharma Letter
After trial failure, J&J ditches Imaavy as combo agent for rheumatoid arthritis
Aug 29, 2025 • FiercePharma
argenx to Present at Upcoming Investor Conferences
Aug 28, 2025 • GlobeNewswire
argenx to Present at Upcoming September 2025 Investor Conferences
Aug 28, 2025 • BioSpace
Stocks Showing Improving Market Leadership: argenx ADR Earns 84 RS Rating
Aug 27, 2025 • Investor's Business Daily
Argenx Stock Hits Record High After Reporting 664% Earnings Surge; This Rating Upgraded
Aug 26, 2025 • Investor's Business Daily
Late-stage trial boost for Argenx’s myasthenia gravis drug Vyvgart
Aug 26, 2025 • European Pharmaceutical Review
Argenx Eyes ‘Broadest Label’ for Vyvgart in Myasthenia Gravis After Positive Phase III Data
Aug 26, 2025 • BioSpace
Piper Sandler raises argenx stock price target to $820 on Vyvgart success
Aug 26, 2025 • Investing.com
argenx seeks broader myasthenia gravis label for Vyvgart after Phase III success
Aug 25, 2025 • FirstWord Pharma
argenx stock rating reiterated at Outperform by RBC on Vyvgart success
Aug 25, 2025 • Investing.com
With late-stage trial win, Argenx preps FDA filing to push Vyvgart into broader myasthenia gravis population
Aug 25, 2025 • Fierce Pharma
Argenx poised to expand Vyvgart market off new phase 3 data
Aug 25, 2025 • pharmaphorum
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Aug 25, 2025 • Yahoo Finance
Argenx Tops Buy Point On Bullish Study, 850 Price Target
Aug 25, 2025 • Investor's Business Daily
Breakthrough: VYVGART Shows First-Ever Success Across All Seronegative gMG Subtypes in Phase 3 Trial
Aug 25, 2025 • Stock Titan
Argenx shows positive Vyvgart results in Adapt Seron study
Aug 25, 2025 • MarketScreener
Argenx's Phase 3 Study of Potential Neuromuscular Autoimmune Disease Treatment Meets Primary Endpoint
Aug 25, 2025 • MarketScreener
Argenx SE Announces Positive Topline Results from ADAPT Seron Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Aug 25, 2025 • MarketScreener
Argenx Targets FDA Label Expansion After Vyvgart Trial Success
Aug 25, 2025 • Benzinga.com
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Aug 25, 2025 • Morningstar.com
Argenx initiated with bullish view at RBC Capital, here's why
Aug 25, 2025 • thefly.com
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Aug 25, 2025 • BioSpace
Argenx's Vyvgart Uptake is Likely to Accelerate, RBC Says
Aug 25, 2025 • MarketScreener
Argenx announces ADAPT SERON study of Vyvgart met primary endpoint
Aug 25, 2025 • thefly.com
argenx Announces Positive Topline Results from ADAPT SERON Study of VYVGART in Patients with AChR-Ab Seronegative gMG
Aug 25, 2025 • argenx SE
Earnings call transcript: Argenx Q2 2025 reports robust earnings beat
Aug 21, 2025 • Investing.com
Breakthrough in Neuromuscular Disease: argenx Reveals ARGX-119 Program for ALS, CMS, and SMA Treatment
Aug 19, 2025 • Stock Titan
argenx to Host R&D Webinar Highlighting ARGX-119 on September 16, 2025
Aug 19, 2025 • GlobeNewswire
Tennis Icon Monica Seles and Argenx Form Collaboration to Raise Awareness of Myasthenia Gravis
Aug 13, 2025 • Pharmaceutical Executive
Tennis legend Monica Seles, Argenx serve myasthenia gravis awareness at U.S. Open
Aug 12, 2025 • Medical Marketing and Media
argenx and Tennis Legend Monica Seles Team Up to Raise Awareness of Myasthenia Gravis
Aug 12, 2025 • GlobeNewswire
Argenx serves up Monica Seles collab, US Open sponsorship for myasthenia gravis awareness
Aug 12, 2025 • Fierce Pharma
Tennis star Monica Seles reveals shocking battle with Myasthenia Gravis, a rare autoimmune disease
Aug 12, 2025 • Livemint.com
Chronic Inflammatory Demyelinating Polyneuropathy Market Report 2025 | Distribution Channel, Route of Administration, and Region Analysis and Forecast to 2035
Aug 11, 2025 • Research and Markets
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of argenx SE - ARGX
Aug 9, 2025 • Morningstar.com
Here’s What Pulled Down Argenx (ARGX) in Q2
Aug 7, 2025 • Yahoo Finance
Dollar's Worst Start Since 1970s Could Dent European Corporate Profits
Aug 5, 2025 • Benzinga.com
Argenx price target raised by EUR 105 at Deutsche Bank
Aug 4, 2025 • thefly.com
argenx SE (ARGNF) (Q2 2025) Earnings Call Highlights: Record Growth and Strategic Advancements
Aug 1, 2025 • Yahoo Finance
BofA Securities raises argenx stock price target to $880 on strong Vyvgart sales
Jul 31, 2025 • Investing.com
argenx Earnings: VYVGART Sales Nearly Double to $949M with Major Pipeline Breakthroughs
Jul 31, 2025 • Stock Titan
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Jul 31, 2025 • BioSpace
Microsoft, Meta, Comcast and Biogen rise premarket; Qualcomm falls
Jul 31, 2025 • Investing.com
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Jul 31, 2025 • argenx SE
Argenx reports Q2 EPS $3.74, consensus $3.05
Jul 31, 2025 • thefly.com
argenx Reports Half Year 2025 Financial Results and Provides Second Quarter Business Update
Jul 30, 2025 • Morningstar.com
Dermatomyositis Treatment Market Analysis 2025 – Insights for Long-Term Investment & Planning
Jul 29, 2025 • EIN Presswire